Provided by Tiger Fintech (Singapore) Pte. Ltd.

AIM ImmunoTech

0.1339
+0.00090.68%
Volume:343.31K
Turnover:45.75K
Market Cap:9.21M
PE:-0.29
High:0.1414
Open:0.1367
Low:0.1300
Close:0.1330
Loading ...

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

GlobeNewswire
·
28 Feb

AIM Vaccine Eyes HK$74.7 Million from Share Placement; Shares Slide 12%

MT Newswires Live
·
28 Feb

AIM Vaccine Announces Placement of New H Shares

TIPRANKS
·
28 Feb

Morgans Keeps Their Buy Rating on Ai-Media Technologies Limited (AIM)

TIPRANKS
·
28 Feb

Hargreave Hale AIM VCT Reduces Share Capital Through Buyback

TIPRANKS
·
28 Feb

CMO Group Shares Plunge on AIM Delisting Proposal

Dow Jones
·
27 Feb

Ai-Media Technologies Ltd (ASX:AIM) (H1 2025) Earnings Call Highlights: Strategic Shift to SaaS ...

GuruFocus.com
·
27 Feb

AIM Vaccine Gets US FDA Clinical Trial Nod for Respiratory Syncytial Virus Jab

MT Newswires Live
·
27 Feb

AIM ImmunoTech Says NYSE American Accepts Plan to Regain Compliance

MT Newswires Live
·
27 Feb

AIM ImmunoTech Announces Nyse American Acceptance of Plan to Regain Listing Compliance

THOMSON REUTERS
·
27 Feb

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

GlobeNewswire
·
27 Feb

AIM Vaccine’s mRNA RSV Vaccine Trial Approved by FDA

TIPRANKS
·
26 Feb

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

THOMSON REUTERS
·
26 Feb

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

GlobeNewswire
·
26 Feb

Zytronic Starts Wind-Down of Business Assets; to Propose AIM Delisting

Dow Jones
·
26 Feb

AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study

MT Newswires Live
·
26 Feb